Newsfile Corp
11 Jun 2026, 02:06 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
The FDA issued a Complete Response Letter (CRL) refusing to approve Disc Medicine's new drug application for bitopertin due to uncertainties requiring additional evidence. — FDA rejection of a lead drug candidate is a primary catalyst for value loss in biotech companies.
-0.80The Rosen Law Firm is investigating potential securities claims and preparing a class action lawsuit against Disc Medicine for allegedly issuing misleading business information. — Legal action creates additional financial liability and reputational risk, though it follows the primary negative news of the FDA CRL.
-0.30Which stocks this story touches
The company received an FDA Complete Response Letter rejecting a drug application, leading to a 22% stock drop and a securities class action investigation.
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is mentioned as the subject of a securities class action investigation by the Rosen Law Firm.
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
PRNewsWire
6h ago
